ArticleFrontiers in public health2026

Cost-effectiveness analysis of combined immunotherapy regimens for non-squamous non-small lung cancer after tyrosine kinase inhibitors resistance.

Mengmeng Teng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.